- Home
- GLBZ vs MRKR Comparison
GLBZ vs MRKR Comparison
Compare GLBZ & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLBZ
- MRKR
- Stock Information
- Founded
- GLBZ 1949
- MRKR N/A
- Country
- GLBZ United States
- MRKR United States
- Employees
- GLBZ N/A
- MRKR N/A
- Industry
- GLBZ Major Banks
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- GLBZ Finance
- MRKR Health Care
- Exchange
- GLBZ Nasdaq
- MRKR Nasdaq
- Market Cap
- GLBZ 14.1M
- MRKR 13.4M
- IPO Year
- GLBZ N/A
- MRKR N/A
- Fundamental
- Price
- GLBZ $5.14
- MRKR $1.13
- Analyst Decision
- GLBZ
- MRKR Strong Buy
- Analyst Count
- GLBZ 0
- MRKR 3
- Target Price
- GLBZ N/A
- MRKR $13.17
- AVG Volume (30 Days)
- GLBZ 4.6K
- MRKR 39.2K
- Earning Date
- GLBZ 05-07-2025
- MRKR 05-27-2025
- Dividend Yield
- GLBZ 1.97%
- MRKR N/A
- EPS Growth
- GLBZ N/A
- MRKR N/A
- EPS
- GLBZ N/A
- MRKR N/A
- Revenue
- GLBZ $11,254,000.00
- MRKR $6,591,080.00
- Revenue This Year
- GLBZ N/A
- MRKR N/A
- Revenue Next Year
- GLBZ N/A
- MRKR N/A
- P/E Ratio
- GLBZ N/A
- MRKR N/A
- Revenue Growth
- GLBZ N/A
- MRKR 99.06
- 52 Week Low
- GLBZ $3.37
- MRKR $0.95
- 52 Week High
- GLBZ $6.99
- MRKR $5.99
- Technical
- Relative Strength Index (RSI)
- GLBZ 50.52
- MRKR 45.44
- Support Level
- GLBZ $4.06
- MRKR $1.09
- Resistance Level
- GLBZ $5.25
- MRKR $1.30
- Average True Range (ATR)
- GLBZ 0.24
- MRKR 0.09
- MACD
- GLBZ -0.00
- MRKR -0.00
- Stochastic Oscillator
- GLBZ 77.77
- MRKR 19.05
About GLBZ Glen Burnie Bancorp
Glen Burnie Bancorp is a bank holding company for The Bank of Glen Burnie. It offers retail and commercial banking services such as checking, savings, loans, mobile banking, online banking, wire transfer, ACH services, debit cards, automated teller machines, and safe deposit boxes among others. The bank generates its revenue in the form of interest income. All of the revenues are earned within the United States.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.